December 2008
Authors : Shin Wakatsuki1 , Jun-ichi Suzuki1,2 , Masahito Ogawa1 , Mayumi Masumura1 , Susumu Muto3 , Tomoko Shimizu4 , Kiyoshi Takayama4 , Akiko Itai3 , Mitsuaki Isobe1
Affliation :
1Tokyo Medical and Dental University, Department of Cardiovascular Medicine, 1-5-45 Yushima, Bunkyo, Tokyo, Japan
†2University of Tokyo, Graduate School of Medicine, Department of Advanced Clinical Science and Therapeutics, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan ; ; junichisuzuki-circ@umin.ac.jp
3Institute of Medicinal Molecular Design, Inc., 5-24-5 Hongo, Bunkyo, Tokyo, Japan
4NB Health Laboratory, A1-659, 3-12-18, Kamiaoki, Kawaguchi, Saitama, Japan
DOI : 10.1517/14728220802551140
Published in : Expert Opin. Ther. Targets Volume 12 Issue 12 2008 pages 1469 1476
Subject: Original Research
Keywords: brain natriuretic peptide , fibrosis , heart failure , inflammation , matrix metalloproteases , myocardial ischemia , remodeling
Please Login to read the full article.
- Stem cell death for cash-crunched Geron, Angiotech, but Mesoblast outlasts them
- Athersys to reshape trial for cell therapy in heart attack after regaining rights
- Boehringer Ingelheim convinces NICE that Pradaxa is cost-effective
- Ono strikes two deals as it shores up mid-stage pipeline
